Fig. 5From: Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNApRNA-EGFRapt-siXBP1 NPs treated inhibits TNBC in vivo. a Tumor growth in different group treated TNBC mice. (mean ± s.d., n = 5). *, p < 0.05. b, c CD31immunostaining of TNBC tumor. Scale bars, 50 µm. d Quantitative RT-PCR analysis of VEGFA, PDK1, GLUT1, and DDIT4 expression in TNBC tumor after pRNA-EGFRapt-siScr plus dox and pRNA-EGFRapt-siXBP1 plus dox treatment. Results are presented relative to β-actin expression. (mean ± s.d., n = 5). ***, p < 0.001Back to article page